Crossmark

Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial

Crossref DOI link: https://doi.org/10.1007/s12032-017-1040-0

Published Online: 2017-11-02

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Walter, I.

Schulz, U.

Vogelhuber, M.

Wiedmann, K.

Endlicher, E.

Klebl, F.

Andreesen, R.

Herr, W.

Ghibelli, L.

Hackl, C.

Wiest, R.

Reichle, A. https://orcid.org/0000-0002-1821-7887
Funding

Funding for this research was provided by:

F. Hoffmann-La Roche
License Information

License valid from 2017-11-02

Document is current

Any future updates will be listed below